Australian Market Community
Our community narratives are driven by numbers and valuation.
Australian Investing Ideas
Global Weekly Picks
Paladin Energy: Betting on the Nuclear Renaissance
The global energy transition has revived interest in nuclear power. As countries search for reliable, low-carbon baseload electricity, nuclear energy is re-entering policy discussions across Europe, North America, and Asia.Read more
DroneShield's Growth Will Drive Revenue Up by 25.39% Amidst New Success
Morningstar snapshot from 11/03/2026: Fair value: A$2.95 Five-star price: A$1.36 — this is my entry point Current price: A$4.02 Valuation: Overvalued Uncertainty: Very High Economic moat: Narrow 2025 revenue: A$216.5m Revenue growth in 2025: 276% Cash balance: A$209.4m Shares outstanding: ~913m Gross margin: ~60.9% Operating margin: ~-1.9% My interest in DroneShield is based on the long-term need for counter-drone technology, but only at the right price. The current conflict involving Iran is another reminder that drones are now a real threat to military assets, energy infrastructure and broader regional security.Read more
CSL: The Dip Is the Opportunity
CSL: The Dip Is the Opportunity Most people look at CSL's stock chart right now and see a problem. Down 35% from its highs, margins cut in half, and a company in the middle of its biggest restructuring in decades.Read more
Overweight on ANN
My view: Ansell (ASX: ANN) is a quality, mid-risk company suited for a long-term investment. It operates within a stable and expanding TAM, supported by rising global safety and healthcare demand.Read more
CSL Limited: Temporary Headwinds for a Long-Term Healthcare Leader
Overview Founded in 1916 and headquartered in Melbourne, Australia, CSL Limited is widely considered the leader in Australian healthcare and one of the largest global biotechnology companies specializing in plasma-derived therapies, vaccines, and treatments. CSL operates through CSL Behring, CSL Seqirus, and CSL Vifor segments, focusing on 3 different fields, including plasma-derived therapies, vaccines and iron deficiency & nephrology therapies.Read more
A stock I’m bullish on is Pro Medicus Limited (ASX: PME), an Australian healthcare technology company that develops medical imaging software
What do I think the business will look like in 5 years time, and why? I believe Pro Medicus will still be focused on providing medical imaging software and radiology workflow solutions to large hospitals and healthcare networks.Read more
AI short positioning & India emerging market opportunties
Contrarian India Bet vs. AI Skepticism : GQG Partners manages $166 billion in assets but has made a controversial strategic wager—maintaining over $24 billion in Indian investments (14% of AUM) while deliberately avoiding AI stocks.Read more
Lynas Rare Earths: Owning the Policy-Backed Growth Regime, Not Just the Ore Body.
Synopsis & Business Model: A Strategic Bottleneck, Not Just a Miner Lynas Rare Earths is best understood as a vertically integrated critical-minerals utility rather than a conventional cyclical miner. It operates one of the world’s highest‑grade rare earth deposits at Mt Weld in Western Australia, with ore concentrated on site and then processed through its cracking and leaching facility in Kalgoorlie and its separation and refining plant in Gebeng, Malaysia.Read more
Mirvac Group is Undervalued and Set for a Rebound
Shares of Mirvac Group, one of Australia’s largest listed property developers, are trading around A$1.93–A$1.95, near the bottom of their A$1.89–A$2.46 52-week range, leaving the company valued at roughly A$7–8 billion. Yet the fundamentals suggest the market may be overly pessimistic.Read more
